Kralj Ivan, Boos Irene, Müller-Bühl Uwe
Diagnostic and Interventional Radiology and Nuclear Medicine, Diakonissenkrankenhaus Karlsruhe-Rüppurr, Karlsruhe, Germany.
Vasa. 2013 Sep;42(5):340-9. doi: 10.1024/0301-1526/a000299.
Advances in stent technology have widened the field of indications for stent treatment of femoro-popliteal artery lesions, however the use of stents in bending arterial segments is restricted because some first- and second-generation nitinol stent designs did not respond well to the mechanical forces of femoro-popliteal segments in motion which pose a substantial risk of stent fracture inducing in-stent-stenosis. New generation nitinol stents are supposed to overcome these limitations but long-term results are rare.
In forty-five patients (mean age 68 y, range 50 - 85) with peripheral arterial disease (TASC II A-C, Rutherford category 2 - 5) forty-six lesions of the superficial femoral artery (37) or popliteal artery (9) were treated [25 high-grade stenoses, mean length 53 mm (range 30 - 145 mm); 21 chronic total occlusions, mean length 74 mm (range 30 - 180 mm)]. 74 % of lesions were located in the mobile bending arterial segments in the distal femoral or the popliteal segment. Clinical reevaluation performed at discharge, at 6, 12, 24, and 36 months included at least the measurement of ankle-brachial index (ABI) and duplex sonography.
Procedural success rate was 100 %. At 6, 12, 24, and 36 months, cumulative primary patency rate was 93.5 %, 84.8 %, 80.5 %, and 74.3 % (SE<10); freedom from target lesion revascularization rate was 95.7 %, 89.2 %, 84.9 %, and 79.3 % (SE<10); Rutherford category and ABI improved in all patients and clinical success was maintained in more than 85 % of patients.
Sustained technical and clinical success and good clinical long-term results were achieved with Misago™ nitinol stent implantation in femoro-popliteal lesions with moderate risk for in-stent-stenosis, and in the distal femoral and popliteal mobile segment.
支架技术的进步拓宽了股腘动脉病变支架治疗的适应症范围,然而,在弯曲动脉段使用支架受到限制,因为一些第一代和第二代镍钛诺支架设计对股腘段运动时的机械力反应不佳,这带来了支架断裂导致支架内狭窄的重大风险。新一代镍钛诺支架理应克服这些局限性,但长期结果罕见。
45例患者(平均年龄68岁,范围50 - 85岁)患有外周动脉疾病(TASC II A - C级,卢瑟福分类2 - 5级),对46处股浅动脉(37处)或腘动脉(9处)病变进行了治疗[25处高度狭窄,平均长度53毫米(范围30 - 145毫米);21处慢性完全闭塞,平均长度74毫米(范围30 - 180毫米)]。74%的病变位于股远端或腘段的活动弯曲动脉段。出院时、6个月、12个月、24个月和36个月进行的临床重新评估至少包括踝肱指数(ABI)测量和双功超声检查。
手术成功率为100%。在6个月、12个月、24个月和36个月时,累积原发性通畅率分别为93.5%、84.8%、80.5%和74.3%(标准误差<10);靶病变血运重建率分别为95.7%、89.2%、84.9%和79.3%(标准误差<10);所有患者的卢瑟福分类和ABI均有所改善,超过85%的患者维持了临床成功。
在有中度支架内狭窄风险的股腘病变以及股远端和腘部活动段植入Misago™镍钛诺支架取得了持续的技术和临床成功以及良好的临床长期结果。